Compare Cassava Sciences Inc (FLNA) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Raytheon Technologies Corp — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Raytheon Technologies Corp trades at $193.1 (market cap $263.80B). The key difference: Raytheon Technologies Corp is far larger — about 4964.2× Cassava Sciences Inc's market cap, and Raytheon Technologies Corp pays a 1.49% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | RTX | |
|---|---|---|
Market Cap | $53.14M | $263.80B |
Sector | Health | Industrials |
52-Week High | $4.64 | $212.16 |
52-Week Low | $1.09 | $149.17 |
Enterprise Value | -$33.43M | $295.92B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
RTX trades at $193.39, down 1.53% today, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.78 exceeding the $1.51 estimate. Revenue grew to $88.6B in 2025, and net income margin improved to 8.03%. Recent contract wins, including a $515 million U.S. Navy radar award (PRNewsWire, June 3, 2026), highlight defense sector strength.
Outlook remains positive with analyst consensus price target of $213.00 (69% buy ratings), though elevated P/E of 36.28 poses valuation risk. Key opportunities include defense spending tailwinds and margin expansion, while risks involve debt levels and geopolitical volatility affecting contracts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
